Pharmacologic or genetic disruption of FAAH showed antihyperalgesia, antianxiety and antidepression without exhibiting deficits in motility, cognition or body temperature [9,10], which suggests that FAAH is an attractive therapeutic target for treatment of pain, inflammation, anxiety, depression and other CNS disorders. The gene discussed is FAAH; the disease is depressive symptom measurement.